{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T06:12:43Z","timestamp":1764655963695},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ejphar.2017.05.036","type":"journal-article","created":{"date-parts":[[2017,5,18]],"date-time":"2017-05-18T16:46:18Z","timestamp":1495125978000},"page":"30-37","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice"],"prefix":"10.1016","volume":"811","author":[{"given":"Makoto","family":"Yoshimura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Shiomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Ohira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mineo","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takao","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2017.05.036_bib1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.4251\/wjgo.v7.i4.17","article-title":"Cancer cachexia, mechanism and treatment","volume":"7","author":"Aoyagi","year":"2015","journal-title":"World J. Gastrointest. Oncol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib2","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/BF03343763","article-title":"Preliminary evidence that Ghrelin, the natural GH secretagogue (GHS)-receptor ligand, strongly stimulates GH secretion in humans","volume":"23","author":"Arvat","year":"2000","journal-title":"J. Endocrinol. Investig."},{"key":"10.1016\/j.ejphar.2017.05.036_bib3","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/ijc.24784","article-title":"Evidence for the contribution of insulin resistance to the development of cachexia in tumor-bearing mice","volume":"126","author":"Asp","year":"2010","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib4","doi-asserted-by":"crossref","first-page":"R893","DOI":"10.1152\/ajpregu.00015.2008","article-title":"Ghrelin inhibits skeletal muscle protein breakdown in rats with thermal injury through normalizing elevated expression of E3 ubiquitin ligases MuRF1 and MAFbx","volume":"296","author":"Balasubramaniam","year":"2009","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib5","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1517\/14712598.2011.627850","article-title":"A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer","volume":"11","author":"Bayliss","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"issue":"11 Suppl","key":"10.1016\/j.ejphar.2017.05.036_bib6","doi-asserted-by":"crossref","first-page":"3465S","DOI":"10.1093\/jn\/132.11.3465S","article-title":"Dietary intake, resting energy expenditure, weight loss and survival in cancer patients","volume":"132","author":"Bosaeus","year":"2002","journal-title":"J. Nutr."},{"key":"10.1016\/j.ejphar.2017.05.036_bib7","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ejphar.2015.02.005","article-title":"Analysis of the ghrelin receptor-independent vascular actions of ulimorelin","volume":"752","author":"Broad","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib8","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1200\/JOP.2016.016832","article-title":"Cancer cachexia: beyond weight loss","volume":"12","author":"Bruggeman","year":"2016","journal-title":"J. Oncol. Pract."},{"key":"10.1016\/j.ejphar.2017.05.036_bib9","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib10","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1093\/jn\/129.3.700","article-title":"Alterations of lipid and cholesterol metabolism in cachectic tumor-bearing rats are prevented by insulin","volume":"129","author":"Costelli","year":"1999","journal-title":"J. Nutr."},{"key":"10.1016\/j.ejphar.2017.05.036_bib11","doi-asserted-by":"crossref","first-page":"3004","DOI":"10.1210\/en.2007-0016","article-title":"Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia","volume":"148","author":"DeBoer","year":"2007","journal-title":"Endocrinology"},{"key":"10.1016\/j.ejphar.2017.05.036_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1006\/clim.2000.4838","article-title":"Interleukin-6 release by cultured peripheral blood mononuclear cells inversely correlates with height velocity, bone age, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 serum levels in children with perinatal HIV-1 infection","volume":"94","author":"de Martino","year":"2000","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib13","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S0149-2918(05)80001-3","article-title":"Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group","volume":"69","author":"Dewys","year":"1980","journal-title":"Am. J. Med."},{"key":"10.1016\/j.ejphar.2017.05.036_bib14","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-med-061509-131248","article-title":"Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies","volume":"62","author":"Dodson","year":"2011","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ejphar.2017.05.036_bib15","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition","volume":"27","author":"Evans","year":"2008","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejphar.2017.05.036_bib16","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib17","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.cmet.2016.10.010","article-title":"Tumor-induced IL-6 reprograms host metabolism to suppress anti-tumor immunity","volume":"24","author":"Flint","year":"2016","journal-title":"Cell Metab."},{"key":"10.1016\/j.ejphar.2017.05.036_bib18","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1158\/1078-0432.CCR-07-1147","article-title":"Daily physical-rest activities in relation to nutritional state, metabolism, and quality of life in cancer patients with progressive cachexia","volume":"13","author":"Fouladiun","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2017.05.036_bib19","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.mehy.2015.09.008","article-title":"A hypothesis for a possible synergy between ghrelin and exercise in patients with cachexia: biochemical and physiological bases","volume":"85","author":"Fuoco","year":"2015","journal-title":"Med. Hypotheses"},{"key":"10.1016\/j.ejphar.2017.05.036_bib20","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/S1471-4914(03)00138-2","article-title":"Molecular mechanisms modulating muscle mass","volume":"9","author":"Glass","year":"2003","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ejphar.2017.05.036_bib21","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2273.2004.00850.x","article-title":"Nutritional challenges in head and neck cancer","volume":"29","author":"Grobbelaar","year":"2004","journal-title":"Clin. Otolaryngol. Allied Sci."},{"key":"10.1016\/j.ejphar.2017.05.036_bib22","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.currproblcancer.2011.01.001","article-title":"Nutritional interventions for cancer-induced cachexia","volume":"35","author":"Gullett","year":"2011","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib23","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0006-291X(02)03028-0","article-title":"Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells","volume":"301","author":"Hanada","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejphar.2017.05.036_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.3322\/canjclin.52.2.72","article-title":"Cancer anorexia-cachexia syndrome: current issues in research and management","volume":"52","author":"Inui","year":"2002","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejphar.2017.05.036_bib25","doi-asserted-by":"crossref","first-page":"C834","DOI":"10.1152\/ajpcell.00579.2003","article-title":"The molecular basis of skeletal muscle atrophy","volume":"287","author":"Jackman","year":"2004","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib26","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib27","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1038\/45230","article-title":"Ghrelin is a growth-hormone-releasing acylated peptide from stomach","volume":"402","author":"Kojima","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.05.036_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1152\/physrev.00012.2004","article-title":"Ghrelin: structure and function","volume":"85","author":"Kojima","year":"2005","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejphar.2017.05.036_bib29","doi-asserted-by":"crossref","first-page":"3299","DOI":"10.1200\/JCO.1999.17.10.3299","article-title":"Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia\/cachexia","volume":"17","author":"Loprinzi","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib30","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/1078-0432.CCR-06-2720","article-title":"Insulin treatment in cancer cachexia: effects on survival, metabolism, and physical functioning","volume":"13","author":"Lundholm","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejphar.2017.05.036_bib31","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1124\/mol.107.034298","article-title":"Identification of the atypical L-type Ca2+ channel blocker diltiazem and its metabolites as ghrelin receptor agonists","volume":"72","author":"Ma","year":"2007","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib32","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1002\/1097-0142(197406)33:6<1607::AID-CNCR2820330620>3.0.CO;2-V","article-title":"Corticosteroid therapy of preterminal gastrointestinal cancer","volume":"33","author":"Moertel","year":"1974","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib33","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0889-8588(18)30460-X","article-title":"Nutritional support and cancer cachexia. Evolving concepts of mechanisms and adjunctive therapies","volume":"5","author":"Ng","year":"1991","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"10.1016\/j.ejphar.2017.05.036_bib34","doi-asserted-by":"crossref","first-page":"E591","DOI":"10.1152\/ajpendo.00073.2004","article-title":"IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1","volume":"287","author":"Sacheck","year":"2004","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2017.05.036_bib35","doi-asserted-by":"crossref","first-page":"R393","DOI":"10.1530\/ERC-16-0130","article-title":"Is there an effect of ghrelin\/ghrelin analogs on cancer? A systematic review","volume":"23","author":"Sever","year":"2016","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib36","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/(SICI)1097-0142(19980201)82:3<553::AID-CNCR18>3.0.CO;2-0","article-title":"Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer: a randomized, placebo-controlled trial","volume":"82","author":"Simons","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib37","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.clnu.2007.03.011","article-title":"Pathophysiology of cancer cachexia: much more than host-tumor interaction?","volume":"26","author":"Skipworth","year":"2007","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejphar.2017.05.036_bib38","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1111\/j.1349-7006.1994.tb02917.x","article-title":"Characterization of mice bearing subclones of colon 26 adenocarcinoma disqualifies interleukin-6 as the sole inducer of cachexia","volume":"85","author":"Soda","year":"1994","journal-title":"Jpn. J. Cancer Res."},{"key":"10.1016\/j.ejphar.2017.05.036_bib39","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1091581815573029","article-title":"Integrated approach to early detection of cardiovascular toxicity induced by a ghrelin receptor agonist","volume":"34","author":"Stokes","year":"2015","journal-title":"Int. J. Toxicol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib40","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1172\/JCI116816","article-title":"Suramin interferes with interleukin-6 receptor binding in vitro and inhibits Colon-26-mediated experimental cancer cachexia in vivo","volume":"92","author":"Strassmann","year":"1993","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ejphar.2017.05.036_bib41","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.regpep.2012.06.003","article-title":"Ghrelin improves body weight loss and skeletal muscle catabolism associated with angiotensin II-induced cachexia in mice","volume":"178","author":"Sugiyama","year":"2012","journal-title":"Regul. Pept."},{"key":"10.1016\/j.ejphar.2017.05.036_bib42","first-page":"2290","article-title":"Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice","volume":"50","author":"Tanaka","year":"1990","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejphar.2017.05.036_bib43","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4103\/0973-1075.73644","article-title":"Treatment of cachexia in oncology","volume":"16","author":"Tazi","year":"2010","journal-title":"Indian J. Palliat. Care"},{"key":"10.1016\/j.ejphar.2017.05.036_bib44","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/35038090","article-title":"Ghrelin induces adiposity in rodents","volume":"407","author":"Tsch\u00f6p","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejphar.2017.05.036_bib45","first-page":"1","article-title":"Ghrelin receptor ligands reaching clinical trials: from peptides to peptidomimetics; from agonists to antagonists","volume":"48","author":"Vodnik","year":"2016","journal-title":"Horm. Metab. Res."},{"key":"10.1016\/j.ejphar.2017.05.036_bib46","first-page":"1393","article-title":"Effects of ghrelin on anorexia in tumor-bearing mice with eicosanoid-related cachexia","volume":"28","author":"Wang","year":"2006","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2017.05.036_bib47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1054\/clnu.1999.0090","article-title":"Provision of rhIGF-I\/IGFBP-3 complex attenuated development of cancer cachexia in an experimental tumor model","volume":"19","author":"Wang","year":"2000","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.ejphar.2017.05.036_bib48","doi-asserted-by":"crossref","first-page":"2625","DOI":"10.1007\/s00520-013-1881-9","article-title":"A systematic review of health-related quality of life instruments in patients with cancer cachexia","volume":"21","author":"Wheelwright","year":"2013","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.ejphar.2017.05.036_bib49","doi-asserted-by":"crossref","first-page":"5992","DOI":"10.1210\/jcem.86.12.8111","article-title":"Ghrelin enhances appetite and increases food intake in humans","volume":"86","author":"Wren","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ejphar.2017.05.036_bib50","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1517\/14656566.2015.1041500","article-title":"Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia (CACS) in nonsmall cell lung cancer","volume":"16","author":"Zhang","year":"2015","journal-title":"Expert Opin. Pharmacother."},{"key":"10.1016\/j.ejphar.2017.05.036_bib51","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/j.cell.2010.07.011","article-title":"Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival","volume":"142","author":"Zhou","year":"2010","journal-title":"Cell"}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917303679?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299917303679?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,12,3]],"date-time":"2019-12-03T17:25:39Z","timestamp":1575393939000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299917303679"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":51,"alternative-id":["S0014299917303679"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.036","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Z-505 hydrochloride, an orally active ghrelin agonist, attenuates the progression of cancer cachexia via anabolic hormones in Colon 26 tumor-bearing mice","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2017.05.036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}